

Don't Fail Them Now

Bridging Diagnostic and Treatment Gaps in **Transthyretin Cardiac Amyloidosis**

Sunday, September 29, 2024

6:30-7:00 AM EDT: Registration & Breakfast

7:00-8:00 AM EDT: Symposium

**CME/NCPD/
CPE-Certified
Live Activity**

Signia by Hilton Atlanta Georgia World Congress Center

Triumph Ballroom F (Second Floor)

159 Northside Drive NW, Atlanta, GA



CO-CHAIR & PRESENTER

Michelle Kittleson, MD, PhD

Smidt Heart Institute
Cedars-Sinai Medical Center
Los Angeles, California



CO-CHAIR & PRESENTER

Senthil Selvaraj, MD, MS, MA

Duke University School of Medicine
Duke Molecular Physiology Institute
Durham, North Carolina



This Satellite Symposium is presented through a collaboration between PVI, PeerView Institute for Medical Education, and the Heart Failure Society of America. The program topic, learning objectives, and faculty have been reviewed and approved by the ASM Satellite Review Committee. Satellite sessions are not a part of the scientific program as planned and executed by the HFSA Program Committee.

Register online: [PeerView.com/24ATTR-CA-Attend](https://www.peerview.com/24ATTR-CA-Attend)

Key Reasons to Attend

- Better recognize patterns of signs and symptoms associated with ATTR-CA
- Know how to apply evidence-based guidelines to diagnose ATTR-CA as early as possible
- Optimize cardiovascular outcomes in ATTR-CA by applying the latest efficacy and safety findings for approved and emerging therapies



**Pre-Register
Now!**

Agenda

- **6:30 AM EDT: Registration & Breakfast**
- **7:00 AM EDT: In-Person & Virtual Symposium**
 - **Welcome and Introduction**
 - **MasterClass 1: Closing the Diagnostic Gaps**
 - **Practicum 1: Approaching Suspected ATTR-CA**
 - **MasterClass 2: Bridging Therapeutic Horizons**
 - **Practicum 2: Individualized Treatment of ATTR-CA**
 - **Key Takeaways and Q&A**
- **8:00 AM EDT: Adjourn**

Register Today!

Activity Description

Transthyretin cardiac amyloidosis (ATTR-CA) leads to cardiomyopathy due to the extracellular accumulation of misfolded transthyretin protein. Alarming, new epidemiologic studies suggest that specific genetic variants that cause the disease are far more common than previously suspected. Recent developments have led to the emergence of targeted therapies that alter the inevitable course of ATTR-CA, transforming it from a progressive, potentially fatal disease into a treatable one. However, healthcare providers must institute these therapies early to optimize outcomes. What's most crucial for cardiologists to know about timely recognition and treatment?

Join PeerView Live and renowned experts for this MasterClass & Practicum on ATTR-CA to improve your clinical acumen! By the end, cardiologists will be better prepared to support patients through the diagnostic and treatment process to give them the best chance possible at long-term, favorable outcomes. From identification of the signs and symptoms of ATTR-CA to early intervention using evidence-based guidelines through creating individualized treatment plans using the latest evidence, this live event has it all! Don't fail your patients now—join us during HFSA ASM and leave better equipped to care for patients with ATTR-CA!

Target Audience

This activity has been designed to meet the educational needs of cardiologists, nurses, pharmacists, and other clinicians involved in the management of ATTR-CA.

Educational Objectives

Upon completion of this activity, participants should be better able to:

- Identify clinical signs and symptoms of ATTR-CA, including in at-risk populations
- Employ evidence-based guidelines for early diagnosis of ATTR-CA
- Apply efficacy and safety findings from clinical trials of emerging therapies for ATTR-CA, considering their implications for reducing CV risk and hospitalization for HF

Accreditation, Support, and Credit



In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from BridgeBio Pharma, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008289-0000-24-075-L01-P

Type of Activity: Knowledge